Durable response of lung carcinoma patients to EGFR tyrosine kinase inhibitors is determined by germline polymorphisms in some immune-related genes.

Fiche publication

Date publication

juillet 2023

Journal

Molecular cancer

Auteurs

Membres identifiés du Cancéropôle Est :
Pr ADOTEVI Olivier , Dr ARNOULD Laurent , Dr BOIDOT Romain , Dr CHAPUSOT Caroline , Dr COUDERT Bruno , Dr FOUCHER Pascal , Pr MARTIN Laurent , Pr WESTEEL Virginie , Dr FAVIER Laure

Tous les auteurs :
Dalens L, Niogret J, Richard C, Chevrier S, Foucher P, Coudert B, Lagrange A, Favier L, Westeel V, Kim S, Adotevi O, Chapusot C, Martin L, Arnould L, Kaderbhai CG, Boidot R

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/37516818

Résumé

Non-small cell lung cancer is a very poor prognosis disease. Molecular analyses have highlighted several genetic alterations which may be targeted by specific therapies. In clinical practice, progression-free survival on EGFR TKI treatment is between 12 and 14 months. However, some patients progress rapidly in less than 6 months, while others remain free of progression for 16 months or even longer during EGFR TKI treatment.